Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Estrella Immunopharma, Inc. (NASDAQ: ESLA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K and other documents related to its clinical, corporate, and capital markets activities. Estrella identifies itself as an emerging growth company, with common stock and publicly traded warrants (ESLAW) registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC.
Through its SEC filings, Estrella reports material events such as milestones in the STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma. For example, Form 8-K filings have furnished press releases announcing completion of dose cohorts, Data Safety Monitoring Board recommendations, and other clinical updates. Filings also document Nasdaq communications regarding the company’s compliance with minimum bid price and market value listing requirements, along with confirmations that these matters were later considered closed.
Estrella’s filings further describe its registered securities, including common stock with a par value per share and warrants exercisable for one share of common stock at a specified exercise price. Investors can review these documents to understand the structure of ESLA and ESLAW, as well as the company’s status as an emerging growth company and the implications for its reporting obligations.
On this page, Stock Titan surfaces Estrella’s SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, listing status updates, financing-related information, and board or governance changes. Real-time updates from the SEC’s EDGAR system, combined with AI explanations of forms such as 8-K and registration statements, can assist investors in interpreting how new filings relate to Estrella’s ARTEMIS® T-cell programs and overall corporate profile.
Estrella Immunopharma director Jia Dengyao filed an initial Form 3 reporting no securities beneficially owned in the company. The form lists Dengyao's relationship to the issuer as a director and provides a business address. Table entries indicate there are no non-derivative or derivative holdings to report, and the reporting person signed the filing certifying the accuracy of the statement.
Estrella Immunopharma, Inc. reported that Nasdaq has confirmed the company is back in full compliance with key continued listing rules. The first Nasdaq letter states Estrella has regained compliance with the minimum bid price requirement, after the company’s common stock maintained a closing bid of at least $1.00 per share for 10 consecutive business days from September 9, 2025 through September 22, 2025. Nasdaq now considers this bid-price matter closed.
The second Nasdaq letter confirms Estrella has also regained compliance with the minimum market value of listed securities requirement, as its market value of listed securities was at least $35,000,000 for 17 consecutive business days from August 28, 2025 through September 22, 2025. With both issues resolved, the company’s Nasdaq listing is no longer under these compliance deficiencies.
Estrella Immunopharma, Inc. reported a change in its leadership structure. On September 22, 2025, the Board of Directors appointed Jia Dengyao as a member of the Board, effective immediately. As of this report, he has not been appointed, and is not expected to be appointed, to any Board committees.
In connection with his appointment, the Company entered into an indemnification agreement with Mr. Jia on substantially similar terms as those provided to its other non-employee directors. This agreement commits Estrella Immunopharma to cover certain reasonable expenses, such as attorneys’ fees, court costs, and expert fees, that Mr. Jia may incur in actions or proceedings arising from his service as a director or in roles he undertakes at the Company’s request.